New Delhi: Swiss biologics contract development and manufacturing organisation ExcellGene SA on Tuesday said it has partnered with Bharat Biotech and the University of Sydney to develop a.
The Coalition for Epidemic Preparedness Innovations (CEPI) on Tuesday announced the latest award under its $200m programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other beta coronaviruses.
CEPI will fund the researchers to conduct activities including immunogen design, preclinical studies, manufacturing process development and a Phase 1 clinical trial.
It will fund the researchers to conduct activities including immunogen design, preclinical studies, and a Phase 1 clinical trial. In this, modified immunogens will be produced in a scalable process with high purity and yield at a low cost.
The Coalition for Epidemic Preparedness Innovations (CEPI) on Tuesday announced the latest award under its USD 200 m programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other beta coronaviruses.